PMID- 31949562
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200121
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 11
IP  - 10
DP  - 2018
TI  - Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated 
      in treating elderly Chinese hepatocellular carcinoma patients.
PG  - 4867-4878
AB  - This study aimed to evaluate the efficacy and safety of drug-eluting bead 
      transarterial chemoembolization (DEB-TACE), and to explore its prognostic factors 
      in elderly Chinese hepatocellular carcinoma (HCC) patients. 93 elderly HCC 
      patients undergoing DEB-TACE were prospectively enrolled. Treatment response was 
      assessed by mRECIST criteriaat1 month post DEB-TACE treatment, and progression 
      free survival (PFS) and overall survival (OS) were calculated. Liver function and 
      adverse events (AEs) within 1 month post DEB-TACE were documented. Complete 
      response (CR) rate and objective response rate (ORR) were 18.3% and 87.1%, 
      respectively. Additionally, medians of PFS and OS were 9.0 months and 21.0 
      months, respectively. Multivariate logistic regression revealed that no factor 
      independently predicted CR achievement, while tumor size >/=5.0 cm and AFP abnormal 
      were independent factors for predicting both shorter PFS and OS, and higher BCLC 
      stage was an independent predictive factor for unfavorable OS. As to safety 
      profiles, the percentages of patients with abnormal TBIL, ALT, AST, and ALP were 
      increased at 1 week, while they were not different at 1 month post DEB-TACE 
      treatment compared with baseline. Most frequent AEs were pain, fever, nausea or 
      vomiting; skin discolorations, myelosuppression, and other AEs were relatively 
      rare. In conclusion, DEB-TACE was efficient and well tolerated in elderly HCC 
      patients, and increased tumor size, abnormal AFP, as well as higher BCLC stage 
      could be independent markers for predicting worse prognosis.
CI  - IJCEP Copyright (c) 2018.
FAU - Zhou, Yiming
AU  - Zhou Y
AD  - Department of Abdominal Surgical Oncology, Zhejiang Cancer Hospital Hangzhou, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20181001
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
PMC - PMC6962908
OTO - NOTNLM
OT  - Elderly
OT  - drug-eluting beads transarterial chemoembolization (DEB-TACE)
OT  - efficacy
OT  - hepatocellular carcinoma (HCC)
OT  - prognostic factor
OT  - safety
COIS- None.
EDAT- 2018/10/01 00:00
MHDA- 2018/10/01 00:01
PMCR- 2018/10/01
CRDT- 2020/01/18 06:00
PHST- 2018/05/15 00:00 [received]
PHST- 2018/07/31 00:00 [accepted]
PHST- 2020/01/18 06:00 [entrez]
PHST- 2018/10/01 00:00 [pubmed]
PHST- 2018/10/01 00:01 [medline]
PHST- 2018/10/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2018 Oct 1;11(10):4867-4878. eCollection 2018.